CARNITOR Drug Patent Profile

Which patents cover Carnitor, and when can generic versions of Carnitor launch?

Carnitor is a drug marketed by Leadiant Biosci Inc and is included in three NDAs.

The generic ingredient in CARNITOR is levocarnitine. There are four drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the levocarnitine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Carnitor

A generic version of CARNITOR was approved as levocarnitine by HIKMA on March 29^th, 2001.

Summary for CARNITOR

US Patents:	0
Applicants:	1
NDAs:	3
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	8
Patent Applications:	4,527
Drug Prices:	Drug price information for CARNITOR
What excipients (inactive ingredients) are in CARNITOR?	CARNITOR excipients list
DailyMed Link:	CARNITOR at DailyMed

See drug prices for CARNITOR

Recent Clinical Trials for CARNITOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Claudia R. Morris	PHASE2
Children's Oncology Group	Phase 3
M.D. Anderson Cancer Center	Phase 2

See all CARNITOR clinical trials

Pharmacology for CARNITOR

Drug Class

Carnitine Analog

US Patents and Regulatory Information for CARNITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	AP	RX	Yes	Yes
Leadiant Biosci Inc	CARNITOR	levocarnitine	TABLET;ORAL	018948-001	Dec 27, 1985	AB	RX	Yes	Yes
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	018948-002	Apr 27, 1988		DISCN	No	No
Leadiant Biosci Inc	CARNITOR	levocarnitine	SOLUTION;ORAL	019257-001	Apr 10, 1986	AA	RX	Yes	Yes
Leadiant Biosci Inc	CARNITOR SF	levocarnitine	SOLUTION;ORAL	019257-002	Mar 28, 2007	AA	RX	Yes	No

Expired US Patents for CARNITOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	6,335,369
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	6,696,493
Leadiant Biosci Inc	CARNITOR	levocarnitine	INJECTABLE;INJECTION	020182-001	Dec 16, 1992	6,429,230

International Patents for CARNITOR

See the table below for patents covering CARNITOR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3050201
Canada	2381187	CARNITINE PAR INTRAVEINEUSE DESTINEE AU TRAITEMENT DE PATIENTS SOUFFRANT D'UREMIE CHRONIQUE SOUMIS A UNE DIALYSE PERIODIQUE (INTRAVENOUS CARNITINE FOR THE TREATMENT OF CHRONIC URAEMIC PATIENTS UNDERGOING PERIODICAL DIALYSIS)
European Patent Office	1257266
World Intellectual Property Organization (WIPO)	0152836

CARNITOR (L-carnitine) Market Dynamics and Financial Trajectory: Pricing, Demand Drivers, Competitive Threats, and Revenue Outlook

Last updated: June 8, 2026

CARNITOR (L-carnitine) is a long-standing metabolic drug with a fragmented competitive landscape driven by (1) chronic-use demand in rare genetic and metabolic disorders, (2) broad OTC-adjacent substitution dynamics in some geographies, and (3) ongoing generic and label-volume competition that compresses branded pricing. Financial trajectory is shaped less by new clinical entrants and more by steady unit demand, discounting, payer access, and the ability to defend proprietary product formats and label-specific indications.

What is CARNITOR’s drug profile and where does it sit in the market?

CARNITOR is a brand of L-carnitine used in metabolic and genetic conditions involving impaired fatty acid oxidation and carnitine transport or biosynthesis. The commercial market is typically characterized by:

• Persistent but diagnosis-constrained demand (rare diseases and specialty prescribing).
• Channel dependence on specialty distribution and payer authorization.
• Price pressure from generics and alternate-brand L-carnitine products.
• Formulation segmentation (e.g., oral solutions vs tablets vs injectables, where applicable in local markets).

Which indications drive CARNITOR volume and payor coverage?

Volume is dominated by patients needing L-carnitine as a chronic or long-term therapy, especially where:

• Inherited metabolic disorders create a carnitine deficiency phenotype.
• Clinicians prescribe L-carnitine in settings involving mitochondrial fatty acid metabolism dysfunction.
• Pediatric use patterns matter because some carnitine deficiency syndromes present early.

Coverage is typically driven by medical necessity criteria, ICD-10 alignment, and prior authorization requirements in managed care.

Is demand seasonal or stable?

Demand is generally stable because treatment is chronic and patient cohorts renew each year. Unit demand can show minor variation from:

• New diagnosis rates and coding intensity.
• Formulary changes and prior-authorization tightening or easing.
• Supply availability events that shift short-term fills across competitors.

How does CARNITOR make money: unit economics, pricing power, and discounting?

CARNITOR’s financial performance tends to follow a classic branded-insignia pattern for older, off-patent small molecules:

• Branded pricing power erodes over time due to therapeutic equivalence and substitution by generics.
• Revenue depends on maintaining access (formularies, pharmacy benefit coverage, and distributor alignment).
• Net price is affected by rebate intensity and channel discounting, especially in larger markets with multiple generic offers.

What drives net revenue: price vs volume?

For older L-carnitine brands, the balance shifts over time:

• Early branded periods: pricing contributes most.
• Later life cycle: volume and access contribute more as price declines.
• Any differentiation is usually formulation, country-specific regulatory status, or label-specific restrictions.

Which cost structure matters most?

Financial margins are shaped by:

• Raw material input costs (L-carnitine synthesis and purification).
• Manufacturing complexity and stability requirements for dosage forms.
• Pharmacovigilance, compliance, and distribution costs for specialty channels.

When do major market inflection points occur for CARNITOR?

CARNITOR’s market inflection points are usually linked to:

• Generic entry windows and label expansions or restrictions.
• Payer formulary moves after competitor offerings increase.
• Regulatory changes that alter the preferred product for a given route (oral vs injectable) or population (adult vs pediatric).

What does competitive pressure look like after generic launches?

After generic penetration, branded revenue typically trends down through:

• Share loss to lower-priced equivalents.
• Reduced utilization where payer step edits shift prescribing.
• Conversion from brand to generic at the pharmacy counter.

How fast does branded share erode?

Erosion is often nonlinear: initial share loss occurs after supply and contracting catch up, followed by a slower drift as prescribers stabilize on default alternatives.

How does competition affect CARNITOR’s financial trajectory by geography?

CARNITOR faces different dynamics across major regions due to:

• Generics maturity and the number of listed equivalents in local formularies.
• Reimbursement rules and physician substitution behavior.
• Licensing and authorized generic arrangements.

What are the typical competitive structures?

Common patterns include:

• Multiple generic manufacturers competing on price.
• Authorized generics or “AB-rated” products capturing higher formulary placement.
• Specialty distributor relationships that steer inventory and availability.

How do tendering and procurement rules shape demand?

In public procurement markets, price competition can be aggressive:

• Brand revenue becomes more sensitive to bid awards.
• Switching between suppliers can occur quickly after tender cycles.

What patent and exclusivity dynamics matter for CARNITOR’s market?

For L-carnitine brands, the key point for market dynamics is that revenue is usually not protected by broad, long-term exclusivity. Instead, the commercial defense is often:

• Product format-specific protections in certain jurisdictions and times.
• Manufacturing process know-how where still relevant.
• Regulatory exclusivity that may be narrow and duration-limited.

Do method-of-use or formulation patents meaningfully slow generic entry?

In many established small molecules like L-carnitine, generic entry speed is typically determined by:

• Whether brand-specific formulations still carry enforceable IP in key markets.
• Whether label-specific language creates prescribing constraints that payers do not fully equate across products.

Because L-carnitine is a generic chemical entity, the IP estate usually provides limited incremental runway versus the major events of generic market entry.

How does FDA status and Orange Book listing status affect CARNITOR’s commercialization?

CARNITOR’s U.S. life-cycle is characterized by:

• Off-patent or near-off-patent status driving widespread generic equivalents.
• Switch patterns influenced by Orange Book listings (whether a reference product remains listed for particular dosage forms).
• Pharmacy benefit navigation based on therapeutically equivalent substitution.

What does FDA regulatory status typically imply for future revenue?

When a brand is no longer driving exclusivity, revenue depends on:

• Remaining as the reference product for specific formulations or strengths.
• Maintaining access where prescriber habits and patient stability prevent rapid switching.
• Managing competitive pricing to retain contract placement.

What generic entry risks exist for CARNITOR?

Generic entry risk for CARNITOR is less about one new entrant and more about:

• Ongoing replenishment of generic supply that increases price competition.
• Additional dosage strengths or route conversions becoming default.
• Authorized generic or label carve-outs that shift substitution dynamics.

What is the practical impact on market pricing?

Generic competition typically results in:

• Lower net prices due to rebate pressure and contract re-pricing.
• Reduced branded gross-to-net spreads.
• Increased volatility of monthly revenue tied to contracting and purchasing cycles.

Which companies compete against CARNITOR and how do they influence pricing?

Competitors generally include:

• Multiple generic L-carnitine manufacturers.
• Alternate carnitine product brands, depending on jurisdiction and route.

Pricing influence is driven by:

• The lowest contracted acquisition price offered to distributors and PBMs.
• Ability to maintain supply continuity and avoid stockouts that create temporary price concessions.

What is the financial trajectory likely to look like: decline, flattening, or rebound?

For older L-carnitine brands, the baseline trajectory is typically:

• Gradual decline after generic penetration.
• Flattening once the market reaches a stable number of generic suppliers and formulary positions.
• Occasional step-down events triggered by procurement cycles or additional generic introductions.

A rebound is usually limited unless:

• A company secures new payer placements through improved access.
• The brand retains a unique formulation advantage under specific reimbursement criteria.
• A shift in guideline practice expands treated patient volumes.

What is the revenue exposure to payer contracting and reimbursement rules?

Payer contracting drives the day-to-day financial reality:

• PBM formulary tiering and preferred pharmacy networks determine realized volume.
• Prior authorization can either protect brand starts or accelerate substitution once edits are removed or tightened.
• Claims audits and medical-necessity documentation can affect acceptance rates and reversals.

How do changes in utilization and diagnosis rates affect CARNITOR revenue?

Even in a generic-heavy market, utilization can sustain revenue:

• Increased diagnosis rates for inborn errors of metabolism expand the treatable population.
• Pediatric treatment initiation can create annual cohort growth.
• Shifts from hospital-administered care to outpatient chronic management change distribution economics.

Key Takeaways

• CARNITOR’s market dynamics are dominated by chronic, diagnosis-limited demand and sustained payer access needs rather than new clinical breakthroughs.
• Financial trajectory is typically price-compressed over time due to generic and multi-source substitution, with revenue increasingly tied to contracting and formulary placement.
• Inflection points come from generic supply expansions, formulary tender cycles, and label or route-specific reimbursement changes.
• The commercial path is usually flattening post-penetration, with limited upside unless access improves or treated population expands.

FAQs

1. How do PBM formulary changes typically impact CARNITOR net revenue after generic entry?
2. Does switching between oral and injectable L-carnitine equivalents change payer authorization outcomes for CARNITOR?
3. What procurement tender cycles most affect L-carnitine branded revenue in public health systems?
4. How do supply disruptions among generic L-carnitine suppliers temporarily shift CARNITOR market share?
5. What label-specific restrictions (age, diagnosis, route) most reduce substitution risk for CARNITOR?

References

1. [No citations were provided in the prompt.]